ResultsIQ

ResultsIQ › Latest results › Artemis Medicare Services Limited

Artemis Medicare Services Limited Q2 FY26 earnings call summary

NSE: ARTEMISMED · BSE: 542919

Earnings call of 12 Nov 2025, summarised by AI from the filing.

International business at 32% of revenue, with focus on offshore offices and camps.

Key takeaways

  1. Driver International business at 32% of revenue, with focus on offshore offices and camps.
  2. Risk Raipur facility may face empanelment delays and competitive intensity.

Original filing on BSE

Artemis Medicare Services Limited Q1 FY27 results

As filed: Revenue ₹287 cr (+13% year on year), EBITDA ₹56.5 cr (+38% year on year), PAT ₹31.4 cr (+50% year on year), EBITDA margin 19.7% (+357 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹279 cr (+16% year on year), EBITDA ₹51.6 cr (+39% year on year), PAT ₹30.3 cr (+32% year on year), EBITDA margin 18.5% (+306 bps). Score 67 of 100, Above trend. Revenue and EBITDA growth were well above the company's own trend; profit growth was below it. EBITDA margin rose 306 bps year on year. Profit rose ₹7.3 cr on a year ago, against ₹9.0 cr the year before. Share price after the results: +1.0% in 28 days (Nifty 500: −2.8%).
  • Q3 FY26: Revenue ₹272 cr (+17% year on year), EBITDA ₹44.6 cr (+20% year on year), PAT ₹22.2 cr (+22% year on year), EBITDA margin 16.4% (+42 bps). Score 51 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA growth was in line with it; profit before exceptional items growth was well below it. EBITDA margin rose 42 bps year on year. Other income 25% of PBT. Profit fell 16% from last quarter. Profit before exceptional items rose ₹5.8 cr on a year ago, against ₹11.0 cr the year before. Share price after the results: −2.5% in 30 days (Nifty 500: −1.9%).
  • Q2 FY26: Revenue ₹275 cr (+14% year on year), EBITDA ₹50.0 cr (+16% year on year), PAT ₹30.0 cr (+36% year on year), EBITDA margin 18.2% (+34 bps). Score 53 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA and profit growth were below it. EBITDA margin rose 34 bps year on year. Profit rose ₹8.0 cr on a year ago, against ₹8.0 cr the year before. Share price after the results: +9.2% in 30 days (Nifty 500: −0.6%).
  • Q1 FY26: Revenue ₹255 cr (+14% year on year), EBITDA ₹41.0 cr (+11% year on year), PAT ₹21.0 cr (+24% year on year), EBITDA margin 16.1% (−51 bps). Score 44 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA growth was below it; profit growth was well below it. EBITDA margin fell 51 bps year on year. Profit fell 9% from last quarter. Profit rose ₹4.0 cr on a year ago, against ₹7.0 cr the year before. Share price after the results: −8.9% in 30 days (Nifty 500: +0.1%).
  • Q4 FY25: Revenue ₹240 cr (+7% year on year), EBITDA ₹37.0 cr (−3% year on year), PAT ₹23.0 cr (+64% year on year), EBITDA margin 15.4% (−147 bps). Score 29 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA growth was well below it; profit growth was above it. EBITDA margin fell 147 bps year on year. Other income 41% of PBT. Profit rose ₹9.0 cr on a year ago, more than the ₹3.0 cr it added the year before. Share price after the results: +3.9% in 30 days (Nifty 500: +3.7%).
  • Q3 FY25: Revenue ₹232 cr (+6% year on year), EBITDA ₹37.0 cr (+16% year on year), PAT ₹21.0 cr (+75% year on year), EBITDA margin 16.0% (+134 bps). Score 36 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA growth was well below it; profit growth was well above it. EBITDA margin rose 134 bps year on year. Other income 33% of PBT. Revenue fell 4% from last quarter. Profit rose ₹9.0 cr on a year ago, more than the ₹2.0 cr it added the year before.
  • Q2 FY25: Revenue ₹241 cr (+7% year on year), EBITDA ₹43.0 cr (+23% year on year), PAT ₹22.0 cr (+57% year on year), EBITDA margin 17.8% (+229 bps). Score 69 of 100, Above trend. EBITDA margin rose 229 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Artemis Medicare Services Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.